In melanoma, mesothelioma, and breast cancer, TGFBI overexpression suppressed proliferation and malignant potential [65,66,67]; however, targeting TGFBI may be associated with an increased risk of chemo-resistance in these patients. The gene discussed is TGFBI; the disease is breast carcinoma.